Lonza: Contract to generate research grade iPSCs by the National Institutes of Health Center for Regenerative Medicine

21-Feb-2013 - USA

The National Institutes of Health Center for Regenerative Medicine (NIH) has awarded Lonza Walkersville, Inc. a contract to generate induced pluripotent stem cells (iPSCs) for research purposes.

By definition, iPSCs have the ability to indefinitely self-renew and become any cell type in the body. Because of these attributes, iPSCs have become an important scientific tool and are spurring advancements in basic research, disease modeling, drug development, and regenerative medicine.

The contract awarded to Lonza is deemed an Indefinite Delivery/Indefinite Quantity (IDIQ) award which is a type of United States Government contract that provides an indefinite quantity of services for a fixed amount of time.  For IDIQs, although nothing is guaranteed, minimum and maximum quantity limits are specified in the basic contract as either number of units (for supplies) or as dollar values (for services). The Lonza contract is a three year agreement with a value up to $6.9 million dollars.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances